Parameter
| Biomarker | BCL6 | Full name | B-cell lymphoma 6 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction of treatment response and drug resistance | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (RNA sequencing, Western blot) | ||
| Pathobiological Mechanisms | Recruitment of HDAC inhibitors: Cidabine inhibits the effect of lenalidomide, which degrades BCL6. | ||||
| Clinical Availability Status | Validation phase: Cell line and partial tissue validation, requiring prospective trials and optimization of scoring thresholds. | ||||
| Notes and Dynamics | Conducting clinical trials of combination therapy to validate its efficacy prediction value. | ||||